$281.02
-9.84[-3.38%]
At close: Apr 18
$281.02
0[0.00%]
After Hours: 4:00PM EDT
Bio-Rad Laboratories
(NYSE:BIO)Bio-Rad Laboratories Stock (NYSE:BIO), Analyst Ratings, Price Targets, Predictions
Bio-Rad Laboratories Inc has a consensus price target of $468, established from looking at the 18 latest analyst ratings. The last 3 analyst ratings were released from Citigroup, UBS, and RBC Capital on April 3, 2024, February 16, 2024, and February 16, 2024. With an average price target of $421.67 between Citigroup, UBS, and RBC Capital, there's an implied 50.05% upside for Bio-Rad Laboratories Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
UBS
RBC Capital
Wells Fargo
Credit Suisse
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Bio-Rad Laboratories
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/03/2024 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 29.88% | Citigroup | Patrick Donnelly | $400 → $365 | Downgrade | Buy → Neutral | Get Alert |
| 02/16/2024 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 49.46% | UBS | Dan Leonard | $395 → $420 | Maintains | Buy | Get Alert |
| 02/16/2024 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 70.81% | RBC Capital | Conor McNamara | $484 → $480 | Maintains | Outperform | Get Alert |
| 12/07/2023 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 40.56% | UBS | Dan Leonard | → $395 | Initiates | → Buy | Get Alert |
| 08/07/2023 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 86.82% | Wells Fargo | Dan Leonard | $550 → $525 | Maintains | Overweight | Get Alert |
| 08/04/2023 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 86.46% | RBC Capital | Conor McNamara | $522 → $524 | Maintains | Outperform | Get Alert |
| 08/04/2023 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 95.72% | Credit Suisse | Dan Leonard | $580 → $550 | Maintains | Outperform | Get Alert |
| 06/16/2023 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 95.72% | Wells Fargo | Dan Leonard | → $550 | Initiates | → Overweight | Get Alert |
| 05/08/2023 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 86.82% | Citigroup | Patrick Donnelly | $550 → $525 | Maintains | Buy | Get Alert |
| 05/08/2023 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 88.95% | RBC Capital | Conor McNamara | $582 → $531 | Maintains | Outperform | Get Alert |
| 05/05/2023 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 106.39% | Credit Suisse | Dan Leonard | $680 → $580 | Maintains | Outperform | Get Alert |
| 02/17/2023 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 106.04% | RBC Capital | Conor McNamara | $571 → $579 | Maintains | Outperform | Get Alert |
| 02/17/2023 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 141.98% | Credit Suisse | Dan Leonard | $640 → $680 | Maintains | Outperform | Get Alert |
| 12/07/2022 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 101.05% | RBC Capital | Conor McNamara | → $565 | Initiates | → Outperform | Get Alert |
| 10/28/2022 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 127.74% | Credit Suisse | Dan Leonard | $715 → $640 | Maintains | Outperform | Get Alert |
| 08/25/2022 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 154.43% | Credit Suisse | Dan Leonard | → $715 | Initiates | → Outperform | Get Alert |
| 07/08/2022 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 149.09% | Citigroup | Patrick Donnelly | $750 → $700 | Maintains | Buy | Get Alert |
| 07/30/2021 | BIO | Buy Now | Bio-Rad Laboratories | $281.02 | 230.94% | Wells Fargo | Dan Leonard | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Bio-Rad Laboratories (BIO)?
The latest price target for Bio-Rad Laboratories (NYSE: BIO) was reported by Citigroup on April 3, 2024. The analyst firm set a price target for $365.00 expecting BIO to rise to within 12 months (a possible 29.88% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bio-Rad Laboratories (BIO)?
The latest analyst rating for Bio-Rad Laboratories (NYSE: BIO) was provided by Citigroup, and Bio-Rad Laboratories downgraded their neutral rating.
When was the last upgrade for Bio-Rad Laboratories (BIO)?
There is no last upgrade for Bio-Rad Laboratories.
When was the last downgrade for Bio-Rad Laboratories (BIO)?
The last downgrade for Bio-Rad Laboratories Inc happened on April 3, 2024 when Citigroup changed their price target from $400 to $365 for Bio-Rad Laboratories Inc.
When is the next analyst rating going to be posted or updated for Bio-Rad Laboratories (BIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Rad Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Rad Laboratories was filed on April 3, 2024 so you should expect the next rating to be made available sometime around April 3, 2025.
Is the Analyst Rating Bio-Rad Laboratories (BIO) correct?
While ratings are subjective and will change, the latest Bio-Rad Laboratories (BIO) rating was a downgraded with a price target of $400.00 to $365.00. The current price Bio-Rad Laboratories (BIO) is trading at is $281.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.